Organon Expects 2028 ‘Tidal Wave’ For Biosimilars

Firm’s Opdivo And Keytruda Rivals Will Follow Denosumab And Pertuzumab In Coming Years

 
• By David Wallace
  
Amazing, perfect wave - Image
Organon CEO Kevin Ali predicts a ‘tidal wave’ of competition in 2028

More from Biosimilars

More from Products